TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have advanced (unresectable or metastatic) biopsy-proven pancreatic NET (Neuroendocrine Tumor)~Exclusion Criteria:~* Patients with poorly differentiated neuroendocrine cancer are not eligible

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sunitinib arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of Outpatient Oxygen Weaning Strategies in Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infant with birth gestational age ≤ 37 (37 0/7) wks postmenstrual age (PMA) who has requirement for supplemental O2 at time of NICU discharge, as determined by primary NICU team.~* Infant receiving pediatric pulmonology care at the Center for Healthy Infant Lung Development~* Parent aged 18 years or older~* English or Spanish-speaking.~Exclusion Criteria:~* Parents whose infants has presence of pulmonary hypertension at enrollment~* Parents whose infant with syndrome or other diagnosis with known high risk for persistent hypoxia (cardiac disease, Trisomy 21, Pierre-Robin Sequence, etc.)~* Parents whose infant has requirement for O2 flow rate \> 1 L/min or tracheostomy~* Any infants who also require caffeine at discharge from the NICU

- Gender: ALL
- Minimum Age: None
- Maximum Age: 37 Weeks
- Healthy Volunteers: f

Study Arms:
- Arm A:Standard therapy (Type: NO_INTERVENTION): Infants' oxygen will be increased, decreased, or maintained based on brief structured assessments during monthly clinic visits. Polysomnograms will be utilized prior to final discontinuation of oxygen. RHO will only be utilized on the night prior to and during the polysomnogram to compare these two modalities.
- Arm B:RHO (Type: EXPERIMENTAL): Infants will have the same monthly clinic assessments as in Arm A, but also will utilize RHO to potentially increase, decrease or maintain oxygen between monthly visits.~Parents will transmit a minimum of 4 days of stored RHO data (min 8 hrs per day) every 4-7 days. Changes in oxygen needs will be made based on standardized objective criteria. To determine discontinuation of oxygen, RHO will be utilized instead of polysomnography.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Childhood Malaria Prevention With Maloprim in The Gambia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* For original trial: Children aged 3-59 months present in participating villages~* For follow-up: Children who were in original trial for at least 1 year.~Exclusion Criteria:~* For original trial: None~* For follow-up: Children with mental or physical disabilities who were unable to do cognitive tests

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 59 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be able to verbalize understanding of consent form~2. Be male or female adult volunteers ages 18-65 inclusive.~3. Have a Diagnostic and Statistical Manual-5 (DSM-5) diagnosis of cocaine use disorder, moderate to severe in early remission~4. Have a Body Mass Index (BMI) of 17.5 to 39.9 kg/m2; and a total body weight of at least 45 kg (99 lbs.)~5. Have a history and brief physical examination that demonstrate no clinically significant contraindication for participating in the study, and/ or significant or unstable medical or psychiatric illness.~Exclusion Criteria:~1. Have a current DSM-5 substance use disorder, mild, moderate, or severe, on any drug of abuse other than nicotine, caffeine, and cocaine use disorder in early remission verified by Urine Drug Screen (UDS). Alcohol use disorder and marijuana use disorder, mild without withdrawal symptoms, will be permitted.~2. Have any previous medically adverse reaction to CLAV, Augmentin, penicillin, Ticarcillin, cephalosporin, or any beta-lactam drug.~3. Have any illness, condition, and use of medications, in the opinion of the principal investigator, sub-investigators which would preclude safe and/or successful completion of the study.~4. Report having human immunodeficiency virus (HIV) infection or test positive for HIV during screening~5. Be pregnant (females).~6. Unable to tolerate MRI scan for duration of 60 minutes for physical or psychological reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Clavulanic Acid (Type: EXPERIMENTAL): Participants will receive 10 days of CLAV-- Period 1: 500 mg/day for days 1-3; Period 2: 750 mg/day for days 4-6; Period 3: 1000 mg/day for days 7-10.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive 10 days of placebo and will have a dose escalation at the same time as the experimental group. They will be given additional placebo pills to match the number given to the experimental group (i.e. 2 PBO capsules/day for days 1-3, 3 PBO capsules/day days 4-6 and 4 PBO capsules/day for days 7-10).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and non-pregnant, non-lactating women having a diagnosis of Lower Back Pain (LBP) of non-malignant origin present for at least 3 months~* Patients taking analgesic medications for at least 3 months prior to screening and/or dissatisfied with their current therapy~* Patients requiring opioid treatment must be taking daily doses of opioid-based analgesic, equivalent to \< 160 mg of oral morphine~* Baseline score of =5 on an 11-point numerical rater scale, calculated as the average pain intensity during the last 3 days prior to randomization.~Exclusion Criteria:~* History of alcohol and/or drug abuse in Investigator's judgement~* History of significant liver insufficiency~* chronic hepatitis B or C, or HIV, presence of active hepatitis B or C within the past 3 months~* Life-long history of seizure disorder or epilepsy~* History of malignancy within past 2 years, with exception of basal cell carcinoma that has been successfully treated~* Uncontrolled hypertension~* Patients with severely impaired renal function~* Patients with moderate to severly impaired hepatic function or with laboratory values reflecting inadequate hepatic function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): tapentadol (CG5503) ER 50 100 150 200 250 mg twice daily for 15 weeks
- 002 (Type: ACTIVE_COMPARATOR): oxycodone CR 10 20 30 40 50 mg twice daily for 15 weeks
- 003 (Type: PLACEBO_COMPARATOR): placebo matching placebo twice daily for 15 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* healthy 2-10 years of age children, inclusive and for whom, after the nature of the study has been explained, the parent or legal guardian has provided written informed consent~* who are available for all visits and telephone calls scheduled for the study~* who are up-to-date with age-appropriate routine childhood vaccinations~Exclusion Criteria:~* whose parent or legal guardian is unwilling or unable to give written informed consent~* who had a previous or suspected disease caused by N. meningitidis;~* who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s)~* who have received any investigational agents or vaccines within 90 days prior to enrollment~* who have any serious acute, chronic or progressive disease~* who have epilepsy or any progressive neurological disease or history of Guillain Barré Syndrome~* who have a history of anaphylaxis, serious vaccine reactions~* who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from~* who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time~* who have Down's syndrome or other known cytogenic disorders

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- MenACWY-CRM (1 dose) (Type: EXPERIMENTAL): 1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study day 1.
- Licensed polysaccharide vaccine (Type: ACTIVE_COMPARATOR): 1 injection of a licensed meningococcal MenACWY polysaccharide-protein conjugate vaccine administered by intramuscular (IM) injection on study day 1
- MenACWY-CRM (2 doses) (Type: EXPERIMENTAL): 2 injections of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study days 1 and 61.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Groups 1 and 2 Inclusion Criteria:~* HIV-uninfected males or females age 18-50 years old~* Willing to maintain low risk behavior for HIV infection~Groups 1 and 2 Exclusion Criteria:~• Confirmed HIV-infection, pregnancy or lactation, significant acute or chronic disease and clinically significant laboratory abnormalities~Group 3 Inclusion Criteria:~* HIV-infected males or females age 18-65 years old~* Not on antiretroviral therapy with HIV-1 RNA plasma level between 1,000 and 100,000 copies/ml, CD4 cell count ≥ 300 cells/uL~Group 3 Exclusion Criteria:~• Significant acute or chronic medical condition other than HIV infection, and clinically significant laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group 1A HIV-Uninfected (Type: EXPERIMENTAL): PGDM1400 low dose
- Group 1B HIV-Uninfected (Type: EXPERIMENTAL): PGDM1400 mid dose
- Group 1C HIV-Uninfected (Type: EXPERIMENTAL): PGDM1400 high dose
- Group 2A HIV-Uninfected (Type: EXPERIMENTAL): PGDM1400 + PGT121 low dose
- Group 2B HIV-Uninfected (Type: EXPERIMENTAL): PGDM1400 + PGT121 mid dose
- Group 2C HIV-Uninfected (Type: EXPERIMENTAL): PGDM1400 + PGT121 high dose
- Group 3A HIV-infected off ART (Type: EXPERIMENTAL): PGDM1400 + PGT121 + VRC07-523LS at 20mg/kg; HIV+ without ART
- Group 3B HIV-infected off ART (Type: EXPERIMENTAL): PGDM1400 + PGT121 at high dose; HIV + without ART

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PROmotion of FLU Vaccine Uptake in the Emergency Department - PROFLUVAXED

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults~2. Presenting to ED~3. Not already vaccinated for influenza in the current year~4. Able to provide informed consent~5. Fluent in English or Spanish~6. Anticipated ability to complete study intervention in ED i.e., able to watch a 3-minute videoclip~Exclusion Criteria:~1. Age \< 18 years~2. Major trauma such that it will preclude survey~3. Inability to participate in a survey because of intoxication, altered mental status, or critical illness~4. Incarceration~5. Psychiatric hold~6. We will also exclude patients who state that they have already received an influenza vaccine and patients who are in the ED for suspected acute Covid or influenza illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Question (Q) (Type: EXPERIMENTAL): Subjects receive no vaccine messaging, but are asked a question about whether they would accept a vaccine
- Messaging (M) (Type: EXPERIMENTAL): Subjects receive vaccine messaging and are asked a question about whether they would accept a vaccine
- Non intervention (Type: NO_INTERVENTION): Usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients hospitalized due to acute decompensated HF episode (ADHF) as primary diagnosis) and consistent Signs \& Symptoms~2. Diagnosis of HF New York Heart Association class II-to-IV and reduced ejection fraction: Left ventricular ejection fraction ≤ 40% at Screening~3. Patients did not receive any IV vasodilators (except nitrates), and/or any IV inotropic therapy from the time of presentation for ADHF to Randomization~4. Stabilized (while in the hospital) for at least 24 hours leading to Randomization.~5. Meeting one of the following criteria:~   * Patients on any dose of ACEI or ARB at screening~  * ACEI/ARB naïve patients and patients not on ACEI or ARB for at least 4 weeks before screening.~Exclusion Criteria:~1. History of hypersensitivity to the sacubitril, valsartan, or any ARBs, NEP inhibitors or to any of the LCZ696 excipients.~2. Symptomatic hypotension and/or a SBP below 110 mm Hg or SBP above 180 mm Hg prior to randomization~3. End stage renal disease at Screening; or estimated GFR below 30 mL/min/1.73 m2 (as measured by MDRD formula at Randomization.~4. Serum potassium above 5.4 mmol/L at Randomization.~5. Known history of hereditary or idiopathic angioedema or angioedema related to previous ACE inhibitor or ARB therapy~6. Severe hepatic impairment, biliary cirrhosis and cholestasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-discharge treatment initiation (Type: OTHER): Patients received first dose at any point after Randomization but no later than 12 h before discharge.
- Post-discharge treatment initiation (Type: OTHER): Patients received first dose after discharge and up to 14 days thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female at least 9 years of age and older;~2. Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit);~3. Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator's Global Severity assessment at the baseline visit;~4. Subjects with facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 20 but no more than 50;~5. Subjects with facial acne non-inflammatory lesion (open and closed comedones) count no less than 25 but no more than 100;~6. Subjects with two or fewer facial nodules~Exclusion Criteria:~1. Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study;~2. Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis, dermatitis, eczema;~3. Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;~4. Subjects with a facial beard or mustache that could interfere with the study assessments;~5. Subjects with more than two (2) facial nodules;~6. Evidence or history of cosmetic-related acne

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- IDP-123 Lotion (Type: EXPERIMENTAL): Tazarotene 0.045% Lotion
- IDP-123 Vehicle Lotion (Type: PLACEBO_COMPARATOR): Vehicle Lotion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial of Mental Health Peer-Led Education

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of mental illness~* Disability due to mental illness~* Age 18 years or older~* Willingness to receive the intervention~Exclusion Criteria:~* Inability to understand spoken English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- BRIDGES Intervention (Type: EXPERIMENTAL): The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a 10-week course to an 8-week course, meeting for 2 1/2 hours once a week.
- Comparison Wait-list Group (Type: NO_INTERVENTION): Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend the BRIDGES program after their final research interview.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years.~* Must have received prior therapy for their WM and have relapsed or refractory WM. Any number of prior therapies is acceptable.~* Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level of \> 2 times the upper limit of each institution's normal value is required and over 10% of lymphoplasmacytic cells in the bone marrow.~* ECOG Performance Status (PS) 0, 1, or 2.~* The following laboratory values obtained 14 days prior to registration~* ANC \>= 1 x109/L~* PLT \>= 75 x109/L~* Total bilirubin ≤ 2.0 mg/dL (If total is elevated check direct and if normal patient is eligible.)~* AST \<= 3 x upper limit of normal (ULN)~* Creatinine \<= 2 x ULN~* Ability to provide informed consent.~* Life expectancy \>= 12 weeks.~Exclusion Criteria:~* Uncontrolled infection.~* Other active malignancies.~* CNS involvement.~* Cytotoxic chemotherapy ≤ 3 weeks, or biologic therapy ≤ 2 weeks, or corticosteroids ≤ 2 weeks, prior to registration. Patients may be receiving chronic corticosteroids if they are being given for disorders other than WM such as auto-immune diseases. Plasmapheresis is not considered as an active therapy and can be used at the physician's discretion.~* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational.~* Any of the following:~* Pregnant women~* Nursing women~* Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device (IUD), or abstinence, etc.)~* Known to be HIV positive.~* Radiation therapy ≤ 2 weeks prior to registration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perifosine (Type: EXPERIMENTAL): Patients will receive perifosine orally at 150 mg daily after food for 28-d cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete